Dalton Announces Release of White Paper on Risk Sharing

Share Article

Dalton releases white paper on risk sharing in sponsor-CMO relationships.

In my experience, the most satisfactory contracts are those which bind the parties in a 'joined at the hip' relationship.

Dalton Pharma Services, a leading provider of drug discovery, development and manufacturing services to pharmaceutical and biotechnology companies, today announced that the company has released its white paper on Risk Sharing in Sponsor-CMO contracts.

In the white paper, entitled “Towards Equitable Risk Relationships: Views on Risk Sharing in Sponsor-CMO Contracts,” Peter Pekos, CEO of Dalton Pharma, shares his experiences and thoughts on a wide variety of risk sharing approaches Dalton Pharma Services has successfully utilized over the last 25 years. From materials management to IP rights, the paper addresses many aspects of risk that influence the structures of contracts and relationships with sponsors.

The full white paper is available for download on the Dalton website at http://www.dalton.com.

“In my experience, the most satisfactory contracts are those which bind the parties in a “joined at the hip” relationship,” said Peter Pekos, CEO of Dalton Pharma. “When we speak of contractual risk, we are looking for an alignment of risk and appropriate protections for both parties.”

About Dalton:

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a GMP contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its modern cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

Further information can be found at http://www.dalton.com.

For further information, contact:

Peter Pekos
President & CEO
Dalton Pharma Services Inc.
349 Wildcat Road
Toronto, Ontario
Tel: 416-661-2102

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Pekos
Visit website